Academic Journal
TREATMENT ADHERENCE IN PATIENTS WITH OSTEOPOROSIS IN DAILY CLINICAL PRACTICE ; Приверженность лечению больных остеопорозом в реальной клинической практике
| العنوان: | TREATMENT ADHERENCE IN PATIENTS WITH OSTEOPOROSIS IN DAILY CLINICAL PRACTICE ; Приверженность лечению больных остеопорозом в реальной клинической практике |
|---|---|
| المؤلفون: | N. Toroptsova V., O. Nikitinskaya A., O. Dobrovolskaya V., Н. Торопцова В., О. Никитинская А., О. Добровольская В. |
| المصدر: | Rheumatology Science and Practice; Vol 52, No 3 (2014); 336-341 ; Научно-практическая ревматология; Vol 52, No 3 (2014); 336-341 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20143 |
| بيانات النشر: | IMA-PRESS, LLC |
| سنة النشر: | 2014 |
| المجموعة: | Rheumatology Science and Practice (E-Journal) / Научно-практическая ревматология |
| مصطلحات موضوعية: | osteoporosis, osteoporotic fractures, treatment adherence, остеопороз, остеопоретические переломы, приверженность лечению |
| الوصف: | Objective: to estimate the frequency of use of antiosteoporotic drugs in daily clinical practice and treatment adherence in patients. Subjects and methods. Questionnaires were used to interview two patient groups: 1) 198 women with osteoporosis (OP) with duration ≥3 years; 2) 186 women over 50 years of age who had sustained low-trauma fractures (LTF) at different sites and undergone assessments of therapy prescription and adherence 12 and 18 months after fracture. Results. In Group 1 patients with OP, 16, 24, and 38% of the women took antiosteoporotic treatment for >3, 2-3, and 6 months to 1 year, respectively; and 22% did not start pathogenetic therapy. Treatment adherence was significantly higher among those who were followed at the specialized OP Center. In Group 2, 56% of the patients had received therapy following LTF and 44% had not, which was due to the absence of primary care physicians' recommendations in half of the cases. 24% were treated after LTF within the first year and only 19% of the women were at 18 months. Treatment was recommended by the specialists of the OP Center in 89% of the cases and by primary care physicians in 11%. Within a year, repeated fracture occurred in 9% of the patients; among them none received pathogenetic treat- ment. A questionnaire survey of the patients indicated that they preferred to use drugs more rarely rather than every day. At the same time no advantages of any one route of drug administration were found. Conclusion. There is a low frequency of using pathogenetic treatment in patients with OP, particularly in those who are followed up in the district outpatient departments, which is due to both the absence of physicians' prescription of antiosteoporotic drugs and inadequate treatment adherence in patients. Both patient motivation to long-term treat- ment and OP education programs among primary care physicians are needed to improve the quality of medical care to osteoporotic patients. ; Цель – оценить частоту назначения противоостеопоретических препаратов в ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://rsp.mediar-press.net/rsp/article/view/1949/1221; Общая заболеваемость взрослого населения России в 2011 году. Статистические материалы. Москва: ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» МЗ РФ; 2012; Ч. 4: С.135–7. [Obshchaya zabolevaemost' vzroslogo nase- leniya Rossii v 2011 godu. Statisticheskie materialy. [The general incidence of adult population of Russia in 2011. Statistical materi- als.] Moscow: FGBU «Tsentral'nyi nauchno-issledovatel'skii insti- tut organizatsii i informatizatsii zdravookhraneniya» MZ RF; 2012; Pt 4: P.135–7.]; World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003.; Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58(4):650–7. DOI: http://dx.doi.org/10.1111/j.1532-5415.2010.02769.x.; Shu AD-H, Stedman MR, Polinski JM, et al. Adherence to osteo- porosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care. 2009;15(7):417–24.; Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti- osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 2008 Oct;90(10):2142–8. DOI: http://dx.doi.org/10.2106/JBJS.G.00864.; Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101.038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435–41. DOI: http://dx.doi.org/10.1359/jbmr.080418.; Simonelli C, Chen YT, Morancey J, et al. Evaluation and manage- ment of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med. 2003 Jan;18(1):17–22. DOI: http://dx.doi.org/10.1046/j.1525-1497.2003.20387.x.; Schurink M, Hegeman JH, Kreeftenberg HG, Ten Duis HJ. Follow-up for osteoporosis in older patients three years after a fracture. Neth J Med. 2007;65(2):71–4.; Astrand J, Thorngren KG, Tagil M. One fracture is enough! Experience with a prospective and consecutive osteoporosis screening program with 239 fracture patients. Acta Orthop. 2006;77(1):3–8. DOI: http://dx.doi.org/10.1080/17453670610045623.; Follin SL, Black JN, McDermott MT. Lack of diagnosis and treat- ment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003 Feb;23(2):190–8. DOI: http://dx.doi.org/10.1592/phco.23.2.190.32090.; Premaor MO, Pilbrow L, Tonkin C, et al. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. QJM. 2010;103(1):33–40. DOI:10.1093/qjmed/hcp154. Epub 2009 Oct 28.; Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporot- ic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2009 Feb;20(2):299–307. DOI: http://dx.doi.org/10.1007/s00198-008- 0651-x.; Astrand J, Thorngren K-G, Tgil M, Еkesson K. 3-year follow-up of 215 fracture patients from a prospective and consecutive osteo- porosis screening program – Fracture patients care! Acta Orthop. 2008;79(3):404–9.; Kuo I, Ong C, Simmons L, et al. Successful direct intervention for osteoporosis in patients with minimal trauma fractures. Osteoporosis Int. 2007;18(12):1633–9. DOI: http://dx.doi.org/10.1007/s00198-007-0418-9.; Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteo- porosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48(3):243–51. DOI: http://dx.doi.org/10.1016/j.maturitas.2003.12.012.; Cramer J, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453–60. DOI: http://dx.doi.org/10.1185/030079905X61875.; Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895–903. DOI: http://dx.doi.org/10.1185/030079905X74862.; Cooper A, Drake J, Brankin E; PERSIST investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896–905. DOI: http://dx.doi.org/10.1111/j.1742-1241.2006.01059.x. Epub 2006 Jun 19.; Hadji P, Felsenberg D, Amling M, et al. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014 Jan;25(1):339–47. DOI:10.1007/s00198-013-2515-2. Epub 2013 Oct 3.; Пядушкина ЕА, Герасимова КВ, Горяйнов СВ и др. Сравнительный фармакоэкономический анализ применения препарата Бонвива® (ибандронат) с целью профилактики переломов при постменопаузальном остеопорозе. Современная ревматология. 2012;(4):89–96. [Pyadushkina EA, Gerasimova KV, Goryainov SV, et al. Comparative pharmacoeco- nomic analysis of the use of Bonviva® (ibandronat) to prevent frac- tures in postmenopausal osteoporosis. Sovremennaya revmatologiya = Modern Rheumatology. 2012;(4):89–96. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2012-771.; https://rsp.mediar-press.net/rsp/article/view/1949 |
| DOI: | 10.14412/1995-4484-2014-336-341 |
| الاتاحة: | https://rsp.mediar-press.net/rsp/article/view/1949 https://doi.org/10.14412/1995-4484-2014-336-341 |
| Rights: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся неэксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.FDE39C08 |
| قاعدة البيانات: | BASE |
| DOI: | 10.14412/1995-4484-2014-336-341 |
|---|